Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections
Open Access
- 20 February 2021
- journal article
- research article
- Published by Elsevier BV in Journal of Infection and Public Health
- Vol. 14 (5), 655-660
- https://doi.org/10.1016/j.jiph.2021.02.006
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and ParamyxovirusesScientific Reports, 2017
- Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging VirusesJournal of Medicinal Chemistry, 2017
- Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeysNature, 2016
- Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study GroupJournal of Virology, 2013
- New respiratory viral infectionsCurrent Opinion in Pulmonary Medicine, 2012
- The Airway Epithelium: Soldier in the Fight against Respiratory VirusesClinical Microbiology Reviews, 2011
- Coronavirus humains (HCoV)Pathologie Biologie, 2009
- Cell-based assays to identify inhibitors of viral diseaseExpert Opinion on Drug Discovery, 2008
- Coronaviruses in poultry and other birdsAvian Pathology, 2005
- Viral-induced neurodegenerative diseaseCurrent Opinion in Microbiology, 1999